Low-Flow Nasal Cannula Hydrogen Therapy
Sano M et al. · J Clin Med Res. 2020;12(10):674–680.
What kind of evidence is this?
Preclinical
Uncontrolled large-animal pharmacokinetic feasibility experiment
Respiratory health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
Spontaneously breathing micro miniature pigs
3 pigs
Measurements during the first hour of inhalation
100% H₂ through a nasal cannula with a separate oxygen mask
H₂ alone from the generator; O₂ was supplied separately, not generated as Brown’s gas.
100% H₂ source gas.
250 mL/min H₂, directly reported.
O₂ was delivered separately by veterinary anesthesia equipment; the O₂ flow was not reported.
No concurrent control group
Outcomes and reported result
Arterial blood H₂ concentration and saturation; delivery feasibility
Arterial H₂ concentrations rose during low-flow delivery in all three pigs. This was a delivery and pharmacokinetic experiment, not a disease-treatment or human clinical study.
Flow, device, methods, results, patents and conflicts checked in the free full text; independent appraisal remains incomplete.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Only three pigs, no comparator and no clinical outcome. Authors disclosed multiple patents related to H₂ delivery; the result cannot establish efficacy in people.
Technical low-flow nasal-cannula delivery in anesthetized micro miniature pigs, not patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 33029275 · DOI: 10.14740/jocmr4267
Open-access full text is available through PMC.
Open-access PMC full text and PubMed record.
2026-08-10